Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says
An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing cancer spread in patients with early breast cancer. The ongoing Phase 3 PALLAS trial had been testing the efficacy of adding Ibrance to conventional endocrine hormone therapy. As a result of the DMC finding, participants currently receiving Ibrance in PALLAS (NCT02513394) will soon receive instructions from their physicians regarding their next steps in treatment. Nevertheless, the patients’ long-term follow-up in the trial will proceed as planned. The decision was announced after the DMC completed a planned efficacy analysis of the study, which had recruited participants from more than 400 clinical sites across 21 countries worldwide. Health authorities and trial investigators have been informed of the decision, according to Pfizer. “This result is not what we hoped for, but we are steadfast in our commitment to advancing the science and care for people living with breast cancer,” Albert Bourla, chairman and CEO of Pfizer, said in a press release. Ibrance is an oral medication that blocks the activity of
Subscribe or to access all post and page content.